GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

13 Nov 2019

China-US trade challenges has led to de-risking by pharma companies.

GVK Bio, a global CRDO, has announced that a crescendo of market conditions and a strong customer pipeline are colliding to deliver strong growth in 2020.

GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

During the past few years, the company has quickly consolidated its customer base in discovery and research services, with a subsequent positive impact on development services – which are now the fastest-growing part of the company.

Manni Kantipudi, Chief Executive Officer, added: “In the last year we have seen record revenues and teen figure growth for the company. But what is interesting is that whilst our research services – for which we are still best known – are growing at twice the market rate, it’s in development services that we are seeing growth running at three times the industry average.”

The company attributes its recent successes to robust regulatory standards and trust built up by pharma companies in the last few years – GVK Bio is now working with customers on some 18 compounds in commercial or late-stage development. Its discovery and development pipeline features more than 400 customers and over 60 molecules in various stages of clinical development.

“While we continue to benefit from our existing research services and our customers are increasingly staying with us now into development, we are also benefiting from wider macro market conditions, and seeing new customers approach us. Over the past year, there has been an influx of interest from Western life sciences firms, looking to diversify their discovery and development services outside of China to mitigate risk. This is in part due to trade tensions, but also due to tightening regulations and safety-related plant closures in China. The resulting disruption in the global supply chain, be it in discovery or development, has led to increasing interest in geographically diverse sourcing strategies, and GVK BIO, with its proven track record, has been a big beneficiary. So when you add this trend to the rise in outsourcing across pharma and the increasing virtualization of biotechs, we are bullish about our growth prospects through 2020 and beyond,” added Mr Kantipudi.

The company has also recently invested in expanding its biologics footprint in its San Francisco bio development subsidiary, Aragen Biosciences. Here, its newly commissioned suites support cell line development and GMP cell banking, in addition to existing capabilities across bioresearch.

“Our customers are always looking to reduce the time taken from discovery through to launch. By integrating our discovery and development efforts, GVK Bio is significantly reducing times for tech transfer, allowing our customers to expedite their clinical development efforts. Quality, delivery, and value are the three pillars around which we have built GVK BIO, with the sole purpose of accelerating our customer's R&D. We have no competing interests. This clear business model, and our success to date, continues to make us an attractive 'Partner of Choice' for both big pharma and biotechs worldwide.” concluded Mr Kantipudi.

Read More

Related news

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

4 Dec 2019

Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.

Read more 
Connectivity, customization and sustainability driving packaging and drug delivery in 2020

Connectivity, customization and sustainability driving packaging and drug delivery in 2020

4 Dec 2019

Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.

Read more 
Eli Lilly unveils shared innovation laboratory in San Francisco

Eli Lilly unveils shared innovation laboratory in San Francisco

3 Dec 2019

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Read more 
Ground-breaking work creates novel oil-in-water nanoemulsions

Ground-breaking work creates novel oil-in-water nanoemulsions

3 Dec 2019

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Read more 
UK experiences a 'baby boom' of new life sciences ventures

UK experiences a 'baby boom' of new life sciences ventures

2 Dec 2019

Unprecedented levels of investment cited as a major force driving the expansion.

Read more 
Pinpoint secures new investment to develop ground-breaking products

Pinpoint secures new investment to develop "ground-breaking" products

29 Nov 2019

The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.

Read more 
New single-use mixing system offers rapid and homogenous mixing

New single-use mixing system offers rapid and homogenous mixing

28 Nov 2019

ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.

Read more 
Worldwide event predicts global pharma trends for 2020

Worldwide event predicts global pharma trends for 2020

27 Nov 2019

Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.

Read more 
UK’s life sciences sector continues to attract talent despite Brexit fear

UK’s life sciences sector continues to attract talent despite Brexit fear

26 Nov 2019

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

Read more 
Dr Reddy’s enters Nutrition Segment with diabetes drink

Dr Reddy’s enters Nutrition Segment with diabetes drink

25 Nov 2019

The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.

Read more